Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

e-Therapeutics Provides Update on Progress of ETS2101 Cancer Trials

Published: Monday, December 24, 2012
Last Updated: Monday, December 24, 2012
Bookmark and Share
Interim data from the trials are expected in H1 2013.

e-Therapeutics plc has provided an update on the clinical trials of its cancer drug ETS2101.

Two phase I studies, one in patients with primary or secondary brain cancer and the other in patients with various solid tumours, remain on track to report final data in Q4 2013 and Q1 2014, respectively.

The phase I studies are designed to select appropriate doses for further trials, assess the safety and pharmacokinetics of ETS2101 and record any initial signs of anti-cancer activity.

They have a dose-escalating design in which successive cohorts of patients receive higher doses of drug until a maximum tolerated dose is identified.

To date 12 patients - two cohorts of three patients in each trial - have been treated. Some patients have completed multiple cycles of treatment with ETS2101; a number continue to be treated having received up to 11 weekly doses.

No patient in either study has so far experienced dose-limiting toxicities or other serious drug-related adverse effects.

Further dose escalation is therefore planned. It is too early to draw any conclusions about the likely maximum tolerated dose of ETS2101 or about other endpoints in the trials.

The brain cancer study is taking place at the UC San Diego Moores Cancer Center in La Jolla, California.

Two UK centres, St James’s University Hospital in Leeds and the Northern Centre for Cancer Care at the Freeman Hospital in Newcastle, are conducting the solid tumour trial.

Target enrolment is 24 patients in the brain cancer study and 45 patients in the solid tumour trial.

Professor Santosh Kesari, MD, PhD, director of neuro-oncology at the Moores Cancer Center, the investigator leading the brain cancer study, said “We are delighted to be evaluating the novel anti-cancer agent ETS2101 at our Center. Though we have so far exposed patients only to relatively low doses of the drug, we are reassured that the findings to date suggest good tolerability as we move to enrol additional patients at increasing doses.”

The next dose levels in the phase I trials will exceed those evaluated in earlier studies of the drug as a potential treatment for traumatic brain injury.

Stephen Self, Development Director at e-Therapeutics, commented, “We are conducting a thorough phase I programme to evaluate ETS2101. With recruitment of patients on track, we look forward to providing further updates in the first half of next year.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

e-Therapeutics Reports Positive Interim Results from UK Phase Ia Trial of ETS2101
ETS2101 well tolerated at all six dose escalations with no serious adverse events attributed to the drug.
Tuesday, April 01, 2014
e-Therapeutics Starts Phase IIb Trial of ETS6103 in Major Depressive Disorder
Company expects to report the results of the trial in the first half of 2015.
Thursday, October 31, 2013
e-Therapeutics to Raise £40 Million
Company to advance lead cancer drug and exploit network pharmacology platform.
Tuesday, February 12, 2013
e-Therapeutics Starts Second Phase I Cancer Trial of ETS2101
Trial will enrol up to 45 patients with solid tumours at UK centres.
Friday, February 01, 2013
e-Therapeutics’ ETS2101 Enters Phase I Clinical Trial in Brain Cancer
First findings are expected in late 2012.
Wednesday, June 20, 2012
e-Therapeutics’ Preliminary Results for the Year Ended 31 January 2012
Further drugs for infection and depression expected to enter trials in 2012.
Friday, June 15, 2012
Phase I Clinical Trials of Cancer Drug ETS2101 Approved by Regulators
Enrolment of patients into trials will begin shortly.
Thursday, March 29, 2012
e-Therapeutics Outlines Goals for 2012
Company announces presentation at biotech showcase conference.
Thursday, March 01, 2012
Prime Minister Opens e-Therapeutics’ Drug Discovery Centre near Oxford
David Cameron opens Company’s new drug discovery centre at Long Hanborough.
Monday, February 27, 2012
Celgene Executive Dr Rajesh Chopra Joins the Board of e-Therapeutics
Dr Chopra has extensive experience of all phases of drug development.
Monday, February 06, 2012
e-Therapeutics Appoints Daniel Elger as Chief Financial Officer
Dr Elger, 41, was previously the VP, Marketing & Communications at cancer drug developer Antisoma plc.
Thursday, July 21, 2011
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
How Do You Kill A Malaria Parasite?
Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite’s skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream. The drugs also seem to trick the parasite into reproducing prematurely.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!